智通财经APP获悉，康诺亚-B(02162)涨近3%，截至发稿，涨2.24%，报57港元，成交额1971.12万港元。
消息面上，据康诺亚-B官微消息，近日，康诺亚和合作伙伴Ouro Medicines Ltd共同宣布，BCMA×CD3双抗CM336(OM336)获美国FDA授予快速通道资格(FTD)认定， 用于治疗自身免疫性溶血性贫血(AIHA)和免疫性血小板减少症(ITP)。CM336在AIHA和ITP两项适应症上获得快速通道资格认定，凸显该类疾病对创新治疗方案的急迫需求，也再次体现CM336在自身免疫性疾病上的治疗潜力。
此前，康诺亚与Ouro Medicines Ltd订立独家许可协议，授予Ouro Medicines在全球(不包括中国内地、香港、澳门及台湾地区)研究、开发、生产、注册及商业化CM336的独家权利。CM336已获得FDA授予的用于治疗AIHA和ITP两项适应症的孤儿药资格认定(ODD)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.